Last reviewed · How we verify
Pipracil (PIPERACILLIN)
Pipracil works by inhibiting bacterial cell wall synthesis, ultimately leading to cell lysis and death.
At a glance
| Generic name | PIPERACILLIN |
|---|---|
| Sponsor | Wyeth Pharms Inc |
| Drug class | piperacillin |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1981 |
Mechanism of action
ZOSYN is an antibacterial drug [see Microbiology (12.4)].
Approved indications
- Abdominal abscess
- Acute gonococcal cervicitis
- Acute gonococcal endometritis
- Acute gonococcal urethritis
- Appendicitis
- Bacterial infection due to Klebsiella pneumoniae
- Bacterial infection due to Serratia
- Bacterial pneumonia
- Bacterial septicemia
- Bacteroides Appendicitis
- Bacteroides Complicated Appendicitis
- Bacteroides Endometritis
- Bacteroides Joint Infection
- Bacteroides Osteomyelitis
- Bacteroides Pelvic Cellulitis
- Bacteroides Pelvic Inflammatory Disease
- Bacteroides Peritonitis
- Bacteroides Pneumonia
- Cesarean Section Infection Prevention
- Clostridium Peritonitis
Boxed warnings
- PHARMACY BULK PACKAGE-NOT FOR DIRECT INFUSION
Common side effects
- Diarrhea
- Constipation
- Nausea
- Headache
- Insomnia
- Rash
- Pruritus
- Fever
- Vomiting
- Dyspepsia
- Abdominal pain
- Candidiasis
Drug interactions
- tobramycin
Key clinical trials
- A Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients (PHASE4)
- Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia (PHASE4)
- Subcutaneous Piperacillin/Tazobactam Compared With Intravenous Treatment (PHASE2)
- Evaluation of the Achievement of a Pharmacodynamic Target of Piperacillin-Tazobactam for the Population With Obesity (PHASE4)
- SYN-004 Safety and Tolerability in Allo-HCT Subjects (PHASE1,PHASE2)
- Aminoglycosides in Early Sepsis (PHASE4)
- Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial (NA)
- Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |